These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 37140357)

  • 81. Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease?
    Hashimoto M; Kazui H; Matsumoto K; Nakano Y; Yasuda M; Mori E
    Am J Psychiatry; 2005 Apr; 162(4):676-82. PubMed ID: 15800138
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Neuroprotective therapeutics for Alzheimer's disease: progress and prospects.
    Palmer AM
    Trends Pharmacol Sci; 2011 Mar; 32(3):141-7. PubMed ID: 21256602
    [TBL] [Abstract][Full Text] [Related]  

  • 83. A study of the potential neuroprotective effect of riluzole on locomotor networks of the neonatal rat spinal cord in vitro damaged by excitotoxicity.
    Sámano C; Nasrabady SE; Nistri A
    Neuroscience; 2012 Oct; 222():356-65. PubMed ID: 22771622
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease.
    Schiefer J; Landwehrmeyer GB; Lüesse HG; Sprünken A; Puls C; Milkereit A; Milkereit E; Kosinski CM
    Mov Disord; 2002 Jul; 17(4):748-57. PubMed ID: 12210870
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Evaluation of Water-Soluble Mannich Base Prodrugs of 2,3,4,5-Tetrahydroazepino[4,3-b]indol-1(6H)-one as Multitarget-Directed Agents for Alzheimer's Disease.
    Purgatorio R; de Candia M; Catto M; Rullo M; Pisani L; Denora N; Carrieri A; Nevskaya AA; Voskressensky LG; Altomare CD
    ChemMedChem; 2021 Feb; 16(3):589-598. PubMed ID: 33156950
    [TBL] [Abstract][Full Text] [Related]  

  • 86. A comparative evaluation of treatments with 17β-estradiol and its brain-selective prodrug in a double-transgenic mouse model of Alzheimer's disease.
    Tschiffely AE; Schuh RA; Prokai-Tatrai K; Prokai L; Ottinger MA
    Horm Behav; 2016 Jul; 83():39-44. PubMed ID: 27210479
    [TBL] [Abstract][Full Text] [Related]  

  • 87. The ABC of Alzheimer's disease: cognitive changes and their management in Alzheimer's disease and related dementias.
    Corey-Bloom J
    Int Psychogeriatr; 2002; 14 Suppl 1():51-75. PubMed ID: 12636180
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Can statin therapy really reduce the risk of Alzheimer's disease and slow its progression?
    Miida T; Takahashi A; Tanabe N; Ikeuchi T
    Curr Opin Lipidol; 2005 Dec; 16(6):619-23. PubMed ID: 16276238
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Riluzole for acute traumatic spinal cord injury: a promising neuroprotective treatment strategy.
    Wilson JR; Fehlings MG
    World Neurosurg; 2014; 81(5-6):825-9. PubMed ID: 23295632
    [TBL] [Abstract][Full Text] [Related]  

  • 90. [Mechanisms of neuroprotective effects of therapeutic acetylcholinesterase inhibitors used in treatment of Alzheimer's disease].
    Takatori Y
    Yakugaku Zasshi; 2006 Aug; 126(8):607-16. PubMed ID: 16880719
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Efficacy of riluzole in the treatment of spinal cord injury: a systematic review of the literature.
    Srinivas S; Wali AR; Pham MH
    Neurosurg Focus; 2019 Mar; 46(3):E6. PubMed ID: 30835675
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Is riluzole a potential therapy for Rett syndrome?
    Tsai SJ
    Med Hypotheses; 2015 Jul; 85(1):76-8. PubMed ID: 25858436
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Rivastigmine in the treatment of Alzheimer's disease: an update.
    Onor ML; Trevisiol M; Aguglia E
    Clin Interv Aging; 2007; 2(1):17-32. PubMed ID: 18044073
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Utilizing Proteomic Approaches to Uncover the Neuroprotective Effects of ACE Inhibitors: Implications for Alzheimer's Disease Treatment.
    Yang MH; Ho TC; Chang CC; Su YS; Yuan CH; Chuang KP; Tyan YC
    Molecules; 2023 Aug; 28(16):. PubMed ID: 37630190
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Early intervention with a small molecule inhibitor for tumor necrosis factor-α prevents cognitive deficits in a triple transgenic mouse model of Alzheimer's disease.
    Gabbita SP; Srivastava MK; Eslami P; Johnson MF; Kobritz NK; Tweedie D; Greig NH; Zemlan FP; Sharma SP; Harris-White ME
    J Neuroinflammation; 2012 May; 9():99. PubMed ID: 22632257
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Rationale of Medication Choices in Patients With Alzheimer's Disease.
    Wee KW; Tong KC
    J Am Med Dir Assoc; 2024 Aug; 25(8):105104. PubMed ID: 38908398
    [No Abstract]   [Full Text] [Related]  

  • 97. Rejecting False Claims from Markov Simulations in Alzheimer's Disease.
    Langley PC
    Innov Pharm; 2023; 14(3):. PubMed ID: 38487379
    [No Abstract]   [Full Text] [Related]  

  • 98. Sigma-1 and Sigma-2 Receptor Modulators as Potential Therapeutics for Alzheimer's Disease.
    Kargbo RB
    ACS Med Chem Lett; 2021 Feb; 12(2):178-179. PubMed ID: 33603961
    [No Abstract]   [Full Text] [Related]  

  • 99. Potential of molecular chaperones for treating Alzheimer's disease.
    Chen G; Johansson J
    Neural Regen Res; 2024 Nov; 19(11):2343-2344. PubMed ID: 38526266
    [No Abstract]   [Full Text] [Related]  

  • 100. Role of fullerenols derivative 3HFWC in the treatment of Alzheimer's disease.
    Ivkovic S; Koruga D
    Neural Regen Res; 2024 Aug; 19(8):1641-1642. PubMed ID: 38103220
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.